- Trials with a EudraCT protocol (422)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (32)
422 result(s) found for: Necrosis.
Displaying page 9 of 22.
EudraCT Number: 2017-004054-41 | Sponsor Protocol Number: KCE-16002 | Start Date*: 2018-05-07 | |||||||||||
Sponsor Name:University Hospitals Leuven | |||||||||||||
Full Title: CareRA2020: Effectiveness of a combination of Methotrexate and a step down glucocorticoid regimen (COBRA-Slim) for remission induction in patients with early Rheumatoid Arthritis (RA), with or with... | |||||||||||||
Medical condition: early active Rheumatoid Arthritis, previously untreated with DMARDs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001534-19 | Sponsor Protocol Number: APHP200015 | Start Date*: 2021-05-21 |
Sponsor Name:AP-HP/DRCI | ||
Full Title: Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction | ||
Medical condition: Left ventricular (LV) thrombus after acute myocardial infarction (AMI) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001575-16 | Sponsor Protocol Number: 2017-02-32-005 | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis | |||||||||||||
Full Title: A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine ... | |||||||||||||
Medical condition: Patients having operable intrahepatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001419-21 | Sponsor Protocol Number: RC19_0042 | Start Date*: 2019-09-16 |
Sponsor Name:CHU de Nantes | ||
Full Title: Optimization of skin preparation to reduce Cutibacterium acnes colonization in superficial and deep samples during prosthetic shoulder surgery in male patients | ||
Medical condition: Cutibacterium acnes infection in shoulder arthroplasty with males | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005723-20 | Sponsor Protocol Number: RC31/20/0445 | Start Date*: 2022-02-10 |
Sponsor Name:CHU de Toulouse | ||
Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease | ||
Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002313-18 | Sponsor Protocol Number: PAMORA-AP_2020 | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:Mech-Sense, Aalborg University Hospital | |||||||||||||
Full Title: The effects of opioid receptor antagonism on acute pancreatitis: An investigator initiated, randomized, placebo-controlled, double-blind clinical trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001302-25 | Sponsor Protocol Number: 2008-0312-08 | Start Date*: 2009-11-05 | |||||||||||
Sponsor Name:Lab for pharmaceutical biology [...] | |||||||||||||
Full Title: Evaluation of the benefits and effects of hypericin Photodynamic therapy (PDT) in the clinical treatment of superficial bladder carcinoma. | |||||||||||||
Medical condition: the study population consists of 10 patients with anatomopathologically proven muscle invasive TCC without metastasis. These patients require a cystoscopy. Before the planned cystoscopy, the bladde... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003374-30 | Sponsor Protocol Number: SONIC-ALA | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||
Full Title: A pilot study to Evaluate the Safety and Feasibility of Sonodynamic Therapy Using the ExAblate MRI-Guided Focused Ultrasound in the Treatment of Cerebral Glioblastomas. | |||||||||||||
Medical condition: IV degree lobar glioblastoma with a diameter of less than 5 cm. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003922-27 | Sponsor Protocol Number: PAM-UMCG-002 | Start Date*: 2024-02-08 |
Sponsor Name:University Medical Center Groningen (UMCG) | ||
Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer | ||
Medical condition: Primary uterine cancer characterized with dMMR | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004403-12 | Sponsor Protocol Number: APHP190871 | Start Date*: 2020-10-26 |
Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS | ||
Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study | ||
Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003244-79 | Sponsor Protocol Number: 20603 | Start Date*: 2020-02-03 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial in... | |||||||||||||
Medical condition: Acute Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) HU (Completed) NL (Completed) DE (Completed) AT (Completed) ES (Completed) SE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003623-20 | Sponsor Protocol Number: JCA-RIT-2007-01 | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona | |||||||||||||
Full Title: Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR). Study o... | |||||||||||||
Medical condition: Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002445-36 | Sponsor Protocol Number: 0001 | Start Date*: 2011-10-31 | ||||||||||||||||
Sponsor Name:Department of Clinical Oncology, Leiden University Medical Center | ||||||||||||||||||
Full Title: Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study | ||||||||||||||||||
Medical condition: Hepatocellular carcinoma, not metastatic | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002442-23 | Sponsor Protocol Number: GS-US-428-4025 | Start Date*: 2017-01-09 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020738-24 | Sponsor Protocol Number: Version 1.2 (20/06/2011) | Start Date*: 2010-10-12 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA) | |||||||||||||
Medical condition: Patients with established Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001190-28 | Sponsor Protocol Number: KCL (Rheum) TACIT Version 2.1 | Start Date*: 2007-05-09 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006644-19 | Sponsor Protocol Number: CRISTAL | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005532-18 | Sponsor Protocol Number: PLX-CLI-03 | Start Date*: 2017-01-02 | |||||||||||
Sponsor Name:Pluristem Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen... | |||||||||||||
Medical condition: Critical Limb Ischemia (CLI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001960-31 | Sponsor Protocol Number: S54348 | Start Date*: 2013-05-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study | ||
Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021018-49 | Sponsor Protocol Number: FOILED | Start Date*: 2012-05-25 | ||||||||||||||||
Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
Full Title: Fish OIL optimal dosE Determination Study | ||||||||||||||||||
Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
